Open for inclusion

A Phase 2, Open-Label, Single Arm study to evaluate the safety and efficacy of Pembrolizumab in participants with recurrent or mestastatic cutanous squamous cell carcinoma

Cancer type: Skin cancer

Phase: II

Principal Investigator: Brydøy Marianne

Country: NO

Keywords: Norway, Bergen

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03284424?term=MK3475-629&cntry=NO&rank=1